Successful immune tolerance in two children with severe haemophilia A

Leenders, Bert

doi:10.17225/jhp.00003

Abstract

Haemophilia A is an X-linked congenital bleeding disorder resulting from a deficiency of factor VIII (FVIII). Therapy to prevent or treat bleeding is by replacement of the missing FVIII. However, as a consequence of treatment, patients with HA may develop inhibitory IgG antibodies to FVIII, termed “inhibitors”. When this occurs, treatment becomes more complex and costly and morbidity increases. Inhibitor formation, occurring in up to 36% of patients with severe HA, is currently one of the most significant complications affecting patients with HA [1,2]. In these two case studies, the management of bleeds in patients with inhibitors, and the long-term inhibitor eradication will be discussed.

References

1. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality, 1977B99. J Thromb Haemost 2004; 2:1047B1054.10.1046/j.1538-7836.2004.00710.x
Search in Google Scholar Back to article
2. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594B598.10.1016/0140-6736(92)90874-3
Search in Google Scholar Back to article
3. Roberts HR, Monroe DM, White GC. The use of recombinate factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858B3864.10.1182/blood-2004-06-222315328151
Open DOI Search in Google Scholar Back to article
4. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1997; 55: 638B648.10.1038/clpt.1994.808004880
Search in Google Scholar Back to article
5. Yatuv R, Dayan I, CarmelBGoren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008; 14: 476B48310.1111/j.1365-2516.2008.01741.x18393980
Open DOI Search in Google Scholar Back to article
6. Weimer T, Wormsbächer W, Kronthaler U, et al. Prolonged inBvivo half life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659B66710.1160/TH07-08-052518392323
Search in Google Scholar Back to article
7. Leissinger C, Gringeri A, Antmen B, et al. AntiBinhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684B92.10.1056/NEJMoa110443522047559
Search in Google Scholar Back to article
8. MancoBJohnson MJ, Abshire TC, Schapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535B544.10.1056/NEJMc07262318003967
Search in Google Scholar Back to article
9. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904B1913.10.1111/j.1538-7836.2007.02663.x17723130
Open DOI Search in Google Scholar Back to article
10. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335B134410.1182/blood-2011-08-36913222101900
Search in Google Scholar Back to article
11. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52B57.10.1055/s-0037-1612943
Search in Google Scholar Back to article
12. Mariani G, Kroner B. Immune Tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186B1193.
Search in Google Scholar Back to article
13. Kruez W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with haemophilia A: a prospective longBterm followBup comparing plasmaBderived and recombinant products. Semin Thromb Hemost 2002; 28: 285B 290.10.1055/s-2002-3266412098090
Open DOI Search in Google Scholar Back to article
13. Kruez W. Immune tolerance and choice of concentrates. In: Lee C, ed. Inhibitors in patients with haemophilia. Oxford: Blackwell Science Ltd. 2002; 55B56.10.1002/9780470757260.ch9
Search in Google Scholar Back to article
14. Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia 2001; 17: 11B16.10.1111/j.1365-2516.2010.02337.x20565546
Search in Google Scholar Back to article

Successful immune tolerance in two children with severe haemophilia A

Abstract

Paradigm

My account